KURA
Price
$10.63
Change
-$0.44 (-3.98%)
Updated
Dec 26, 04:59 PM (EDT)
Capitalization
962.41M
67 days until earnings call
Intraday BUY SELL Signals
LQDA
Price
$34.41
Change
-$1.38 (-3.86%)
Updated
Dec 26, 04:59 PM (EDT)
Capitalization
3.11B
76 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

KURA vs LQDA

Header iconKURA vs LQDA Comparison
Open Charts KURA vs LQDABanner chart's image
Kura Oncology
Price$10.63
Change-$0.44 (-3.98%)
Volume$29.76K
Capitalization962.41M
Liquidia
Price$34.41
Change-$1.38 (-3.86%)
Volume$18.2K
Capitalization3.11B
KURA vs LQDA Comparison Chart in %
KURA
Daily Signal:
Gain/Loss:
LQDA
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
KURA vs. LQDA commentary
Dec 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KURA is a Hold and LQDA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 26, 2025
Stock price -- (KURA: $11.06 vs. LQDA: $35.79)
Brand notoriety: KURA and LQDA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KURA: 27% vs. LQDA: 21%
Market capitalization -- KURA: $962.41M vs. LQDA: $3.11B
KURA [@Biotechnology] is valued at $962.41M. LQDA’s [@Biotechnology] market capitalization is $3.11B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KURA’s FA Score shows that 1 FA rating(s) are green whileLQDA’s FA Score has 1 green FA rating(s).

  • KURA’s FA Score: 1 green, 4 red.
  • LQDA’s FA Score: 1 green, 4 red.
According to our system of comparison, both KURA and LQDA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KURA’s TA Score shows that 4 TA indicator(s) are bullish while LQDA’s TA Score has 3 bullish TA indicator(s).

  • KURA’s TA Score: 4 bullish, 5 bearish.
  • LQDA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, KURA is a better buy in the short-term than LQDA.

Price Growth

KURA (@Biotechnology) experienced а +8.64% price change this week, while LQDA (@Biotechnology) price change was +5.17% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.37%. For the same industry, the average monthly price growth was +0.28%, and the average quarterly price growth was +55.43%.

Reported Earning Dates

KURA is expected to report earnings on Mar 03, 2026.

LQDA is expected to report earnings on Mar 12, 2026.

Industries' Descriptions

@Biotechnology (+0.37% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LQDA($3.11B) has a higher market cap than KURA($962M). LQDA YTD gains are higher at: 204.337 vs. KURA (26.980). LQDA has higher annual earnings (EBITDA): -102.75M vs. KURA (-212.24M). KURA has more cash in the bank: 550M vs. LQDA (157M). KURA has less debt than LQDA: KURA (19.5M) vs LQDA (199M). KURA has higher revenues than LQDA: KURA (104M) vs LQDA (69.2M).
KURALQDAKURA / LQDA
Capitalization962M3.11B31%
EBITDA-212.24M-102.75M207%
Gain YTD26.980204.33713%
P/E RatioN/AN/A-
Revenue104M69.2M150%
Total Cash550M157M350%
Total Debt19.5M199M10%
FUNDAMENTALS RATINGS
KURA vs LQDA: Fundamental Ratings
KURA
LQDA
OUTLOOK RATING
1..100
5884
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
91
Overvalued
PROFIT vs RISK RATING
1..100
1005
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
4035
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KURA's Valuation (32) in the Biotechnology industry is somewhat better than the same rating for LQDA (91) in the Pharmaceuticals Major industry. This means that KURA’s stock grew somewhat faster than LQDA’s over the last 12 months.

LQDA's Profit vs Risk Rating (5) in the Pharmaceuticals Major industry is significantly better than the same rating for KURA (100) in the Biotechnology industry. This means that LQDA’s stock grew significantly faster than KURA’s over the last 12 months.

KURA's SMR Rating (98) in the Biotechnology industry is in the same range as LQDA (100) in the Pharmaceuticals Major industry. This means that KURA’s stock grew similarly to LQDA’s over the last 12 months.

LQDA's Price Growth Rating (35) in the Pharmaceuticals Major industry is in the same range as KURA (40) in the Biotechnology industry. This means that LQDA’s stock grew similarly to KURA’s over the last 12 months.

LQDA's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as KURA (100) in the Biotechnology industry. This means that LQDA’s stock grew similarly to KURA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KURALQDA
RSI
ODDS (%)
Bearish Trend 3 days ago
72%
Bearish Trend 3 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
87%
Momentum
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
89%
MACD
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 23 days ago
76%
Bullish Trend 5 days ago
85%
Declines
ODDS (%)
Bearish Trend 8 days ago
83%
Bearish Trend 9 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
80%
Aroon
ODDS (%)
N/A
Bullish Trend 3 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
KURA
Daily Signal:
Gain/Loss:
LQDA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VMGRX25.430.11
+0.43%
Vanguard Mid Cap Growth Inv
MLVPX17.960.06
+0.34%
MFS Low Volatility Equity R3
SSHFX45.690.07
+0.15%
Sound Shore Investor
LFLTX15.750.02
+0.13%
Lord Abbett Focused Large Cap Value R5
MGIAX43.83-0.03
-0.07%
MFS International Intrinsic Value A

KURA and

Correlation & Price change

A.I.dvisor indicates that over the last year, KURA has been loosely correlated with XNCR. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if KURA jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KURA
1D Price
Change %
KURA100%
+2.50%
XNCR - KURA
58%
Loosely correlated
-0.13%
VYGR - KURA
57%
Loosely correlated
+2.01%
IMNM - KURA
55%
Loosely correlated
+2.76%
NRIX - KURA
55%
Loosely correlated
+0.36%
CLDX - KURA
54%
Loosely correlated
+0.94%
More

LQDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, LQDA has been loosely correlated with DMAC. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if LQDA jumps, then DMAC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LQDA
1D Price
Change %
LQDA100%
+1.56%
DMAC - LQDA
34%
Loosely correlated
+1.44%
ERAS - LQDA
33%
Poorly correlated
+1.18%
KURA - LQDA
32%
Poorly correlated
+2.50%
EYPT - LQDA
32%
Poorly correlated
-0.65%
GOSS - LQDA
32%
Poorly correlated
+4.72%
More